Yago Nieto

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors
    Y Nieto
    Department of Stem Cell Transplantation and Cellular Therapy
    Ann Oncol 26:2125-32. 2015
  2. pmc Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas Electronic address
    Biol Blood Marrow Transplant 21:1914-20. 2015
  3. doi request reprint Transplantation for refractory germ cell tumors: does it really make a difference?
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX, 77030, USA
    Curr Oncol Rep 15:232-8. 2013
  4. pmc Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 19:410-7. 2013
  5. pmc High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies
    Yago Nieto
    Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030
    Biol Blood Marrow Transplant 18:1677-86. 2012
  6. doi request reprint High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030, USA
    Curr Opin Oncol 21:150-7. 2009
  7. doi request reprint Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer
    Yago Nieto
    Department of Medical Oncology, Clinica Universitaria de Navarra, Pamplona, Spain
    Cancer Chemother Pharmacol 65:457-65. 2010
  8. ncbi request reprint Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 13:1324-37. 2007
  9. ncbi request reprint Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, Unit 423, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:4405-13. 2007
  10. pmc Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy
    Y Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Cancer 97:391-7. 2007

Collaborators

Detail Information

Publications67

  1. pmc Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors
    Y Nieto
    Department of Stem Cell Transplantation and Cellular Therapy
    Ann Oncol 26:2125-32. 2015
    ....
  2. pmc Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas Electronic address
    Biol Blood Marrow Transplant 21:1914-20. 2015
    ..In conclusion, vorinostat/gemcitabine/busulfan/melphalan is safe and highly active in refractory/poor-risk relapsed lymphomas, warranting further evaluation. This trial was registered at ClinicalTrials.gov (NCI-2011-02891)...
  3. doi request reprint Transplantation for refractory germ cell tumors: does it really make a difference?
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX, 77030, USA
    Curr Oncol Rep 15:232-8. 2013
    ..Prognostic models have been developed that allow to prospectively identify poor prognosis patients that might benefit from novel HDC-based approaches...
  4. pmc Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 19:410-7. 2013
    ..9, P = .008, HR for OS = 1.8, P = .07). Gem-Bu-Mel improved outcomes in this cohort analysis of patients with refractory/poor-risk relapsed HL and merits evaluation in randomized phase III trials...
  5. pmc High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies
    Yago Nieto
    Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030
    Biol Blood Marrow Transplant 18:1677-86. 2012
    ..In conclusion, gemcitabine/busulfan/melphalan is a feasible regimen with substantial activity against a range of lymphoid malignancies. This regimen merits further evaluation in phase II and III trials...
  6. doi request reprint High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030, USA
    Curr Opin Oncol 21:150-7. 2009
    ..We review here the main publications in this field since 2006, focusing on updates of randomized trials comparing HDC with standard-dose chemotherapy...
  7. doi request reprint Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer
    Yago Nieto
    Department of Medical Oncology, Clinica Universitaria de Navarra, Pamplona, Spain
    Cancer Chemother Pharmacol 65:457-65. 2010
    ..We hypothesized that sequential treatment with dose-dense epirubicin/cyclophosphamide (EC) and docetaxel/capecitabine would be active and tolerable in the adjuvant/neoadjuvant setting...
  8. ncbi request reprint Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 13:1324-37. 2007
    ..The resulting gemcitabine/docetaxel/melphalan/carboplatin combination was highly active in refractory cancers and should be further tested in disease-specific trials...
  9. ncbi request reprint Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, Unit 423, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:4405-13. 2007
    ..We hypothesized that EGFR status plays a major prognostic role in this setting, through expression, activation, or the presence of its mutated variant EGFRvIII...
  10. pmc Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy
    Y Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Cancer 97:391-7. 2007
    ..In conclusion, tumour angiogenesis, expressed as MVD, is a major independent prognostic factor in breast cancer patients with extensive axillary involvement...
  11. pmc Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines
    Benigno C Valdez
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Exp Hematol 40:800-10. 2012
    ..This study provides a rationale for an ongoing clinical trial in our institution using (BMG+suberoylanilide hydroxamic acid) as pre-hematopoietic stem cell transplantation conditioning for lymphoma...
  12. pmc Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies
    Partow Kebriaei
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 17:412-20. 2011
    ..Intravenous Bu-Mel was well tolerated. Disease control wa encouraging, and should be explored in larger phase II studies...
  13. pmc Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications
    Benigno C Valdez
    Departments of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Exp Hematol 41:719-30. 2013
    ..Our results provide a rationale for clinical trials incorporating [Gem+Clo] combinations as part of conditioning therapy for high-risk patients with MM undergoing HSCT. ..
  14. pmc A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas Electronic address
    Biol Blood Marrow Transplant 19:1453-8. 2013
    ..6 versus 9.6 months in patients with <VGPR, P = .05). OS was similar across all variables. We conclude that FM100 and FM140 may result in similar patient outcomes after allo-HCT for MM...
  15. doi request reprint Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation
    Li Mei Poon
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Biol Blood Marrow Transplant 19:1059-64. 2013
    ..8). Our data provide more insight into the disease behavior and treatment outcomes of ALL at relapse after HSCT against which future trials may be compared...
  16. pmc Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization
    Veronica R Smith
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Hematol 88:754-7. 2013
    ..93 × 10(6) /kg of body weight. The median CD34+ cell dose collected for patients with multiple myeloma was 8.81 × 10(6) /kg of body weight. Plerixafor was well tolerated; no grade 2 or higher non-hematologic toxic effects were observed...
  17. pmc Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma
    Uday Popat
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 15:718-23. 2009
    ..In patients with multiple myeloma, prior lenalidomide therapy is associated with failure of stem cell mobilization with filgrastim. Remobilization with chemotherapy and filgrastim is usually successful in these patients...
  18. pmc Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life
    Gheath Alatrash
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 17:1490-6. 2011
    ..Our results suggest that age alone should not be the primary reason for exclusion from receiving myeloablative reduced-toxicity conditioning with i.v. Bu-Flu preceding transplantation in patients with AML/MDS...
  19. pmc Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial
    Muzaffar H Qazilbash
    Department of Stem Cell Transplantation and Cellular Therapy, UT M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 14:1401-7. 2008
    ..Addition of ATO + AA to high-dose melphalan is safe and well tolerated as a preparative regimen for MM...
  20. ncbi request reprint Stem cell transplantation outcomes in lymphoblastic lymphoma
    Jonathan E Brammer
    a Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Leuk Lymphoma 58:366-371. 2017
    ..For patients requiring SCT for LBL, CR and TBI-based conditioning prior to allogeneic SCT may provide improved disease control...
  21. pmc Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells
    Benigno C Valdez
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA Electronic address
    Leuk Res 47:100-8. 2016
    ..Our results provide the basis for a clinical trial to evaluate [Flu+Clo+Bu+Rom] as part of conditioning regimen for refractory T-cell malignancy patients undergoing stem cell transplantation. ..
  22. doi request reprint Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia
    Fleur M Aung
    Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Biol Blood Marrow Transplant 22:961-5. 2016
    ..We found that severe pancytopenia is frequently associated with PRCA in 16% of major ABO-incompatible HSCT with a higher incidence in males and pancytopenia resolved with resolution of PRCA in 46% of patients. ..
  23. doi request reprint Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results
    Partow Kebriaei
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas Electronic address
    Biol Blood Marrow Transplant . 2016
    ..OS and NRM rates compare favorably with those for traditional myeloablative total body irradiation-based conditioning regimens...
  24. pmc Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
    Paolo Anderlini
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas Electronic address
    Biol Blood Marrow Transplant 22:1333-7. 2016
    ..With over 50% of patients progression-free at 3 years, allogeneic stem cell transplantation with reduced-intensity conditioning remains an effective and relevant treatment option for Hodgkin lymphoma in the brentuximab vedotin era. ..
  25. doi request reprint Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy
    Benigno C Valdez
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas, USA 77030
    Oncotarget . 2016
    ..Our results further imply the possibility of antagonistic effects when HDAC inhibitors are combined with anthracyclines and other MDR1 drug ligands in chemotherapy...
  26. pmc Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma
    Yago Nieto
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 122:2680-8. 2016
    ..Those observations led to a clinical combination of azacitidine with vorinostat/Gem/Bu/Mel...
  27. ncbi request reprint Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation
    Yago Nieto
    Bone Marrow Transplant Programs, University of Navarra, Pamplona, Spain
    Biol Blood Marrow Transplant 12:217-25. 2006
    ..5%, 50%, and 40%, respectively. In conclusion, the use of tacrolimus/MMF after MSD NST is associated with encouraging rates of GVHD control...
  28. pmc Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation
    Fleur M Aung
    Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 160:798-805. 2013
    ..Hence, after major ABO-mismatched HSCT, the incidence of PRCA was 7·5% and it resolved spontaneously or after withdrawal of immunosuppression in the majority of patients...
  29. ncbi request reprint Docetaxel administered during pregnancy for inflammatory breast carcinoma
    Yago Nieto
    Department of Medical Oncology, University of Navarra, Pamplona, Spain
    Clin Breast Cancer 6:533-4. 2006
    ..After delivery of a healthy child, she underwent surgery, which showed tumor downstaging to pT0 N2, followed by radiation therapy and hormone therapy. This report suggests the safety of docetaxel after the first trimester of pregnancy...
  30. pmc Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study
    Jie Ji
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX
    Exp Hematol 44:458-65. 2016
    ....
  31. pmc Better allele-level matching improves transplant-related mortality after double cord blood transplantation
    Betul Oran
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Haematologica 100:1361-70. 2015
    ..Our data suggest that high resolution typing at 4 loci and selecting cord blood units matched at at least 5/8 alleles may reduce transplant-related mortality after double cord blood transplantation. ..
  32. pmc Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies
    Amin M Alousi
    Department of Stem Cell Transplantation and Cellular Therapies, University of Texas MD Anderson Cancer Center, Houston, Texas Electronic address
    Biol Blood Marrow Transplant 21:906-12. 2015
    ..9; P = .04) with post-CY. The incidence of chronic GVHD and CMV reactivation did not differ. This study suggests that post-CY should not be used as sole GVHD prophylaxis after a RIC transplantation from HLA-matched donors...
  33. doi request reprint Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation
    Carlos A Ramos
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Biol Blood Marrow Transplant 16:686-94. 2010
    ..Our data suggest that seropositivity for HBcAb and seronegativity for HBsAg at the time of transplantation does not seem to adversely affect outcome after allo-HSCT...
  34. pmc Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation
    Syed M Kazmi
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
    Clin Lymphoma Myeloma Leuk 15:687-93. 2015
    ..Conventional cytogenetics and interphase fluorescence in-situ hybridization (FISH) identify a high-risk multiple myeloma population characterized by poor response and short survival...
  35. pmc Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines
    Benigno C Valdez
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Leuk Lymphoma 53:973-81. 2012
    ..Our results provide a preclinical basis for a clinical trial on using [2 NAs + Bu ± SAHA] combinations as conditioning therapy for patients with chemotherapy-refractory lymphoma undergoing HSCT...
  36. pmc Cord-blood engraftment with ex vivo mesenchymal-cell coculture
    Marcos de Lima
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, USA
    N Engl J Med 367:2305-15. 2012
    ..We hypothesized that engraftment would be improved by transplanting cord blood that was expanded ex vivo with mesenchymal stromal cells...
  37. doi request reprint Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma
    Talha Badar
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Eur J Haematol . 2016
    ..Outcome of patients with standard-risk (SR) multiple myeloma (MM) has improved; however, subsets of patients do worse than expected. We sought to identify the factors associated with inferior outcome...
  38. doi request reprint A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation
    Sarah A Milgrom
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer . 2016
    ..The objectives of the current study were to characterize practice patterns and assess the efficacy and toxicity of RT at 2 major transplantation centers...
  39. pmc Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation
    Stefan O Ciurea
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, USA
    Biol Blood Marrow Transplant 18:1835-44. 2012
    ..These results indicate that a TCR graft followed by effective control of GVHD posttransplantation may lower NRM and improve survival after haploidentical SCT...
  40. doi request reprint Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma
    Hong Yang
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Cancer Res 71:5040-9. 2011
    ....
  41. ncbi request reprint A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects
    Roy B Jones
    Department of Blood and Marrow Transplantation, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 10:276-82. 2004
    ..Further, we suggest that amifostine use with BCNU in other contexts and with clinically achievable doses is unlikely to protect the lung from BCNU-associated acute injury...
  42. ncbi request reprint Transplantation of ex vivo expanded cord blood
    Elizabeth J Shpall
    University of Colorado Adult Bone Marrow Transplant Program, Denver, USA
    Biol Blood Marrow Transplant 8:368-76. 2002
    ..This study demonstrates that the CD34 selection and ex vivo expansion of CB prior to transplantation of CB is feasible. Additional accrual will be required to assess the clinical efficacy of expanded CB progenitors...
  43. pmc Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation
    Takuya Sekine
    Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX
    Blood 128:297-312. 2016
    ..Thus, we propose the inclusion of KIR genotyping in graft selection criteria for CBT. HLA-C1/x patients should receive an HLA-C1-KIR2DL2/L3/S2 CB graft, while HLA-C2/C2 patients may benefit from an HLA-C2-KIR2DL1/S1 graft. ..
  44. doi request reprint Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases
    Mariko Yabe
    Departments of Hematopathology Stem Cell Transplantation Lymphoma Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX Biostatistics Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston Department of Pathology, UT Southwestern Medical Center, Dallas, TX Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY Department of Pathology, University of Miami, Miami, FL
    Am J Surg Pathol 40:676-88. 2016
    ..In addition, the outcomes of this patient cohort suggest that stem cell transplantation has value for the treatment of patients with HSTCL. ..
  45. doi request reprint Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation
    Sameh Gaballa
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 122:3316-3326. 2016
    ....
  46. pmc Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports
    Sarah A Milgrom
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, USA
    J Med Case Rep 10:209. 2016
    ..Of these, two patients (5 %) developed graft-versus-host disease within the irradiated tissues during or immediately after radiation therapy...
  47. pmc Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation
    Michal Mego
    1 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 7 Current Address National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovak Republic
    J Cancer 3:369-80. 2012
    ..Conclusion: Our data suggest that CTC and CTCs with EMT are prognostic in MBC patients undergoing HDCT followed by AHSCT...
  48. doi request reprint Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies
    Keiji Shinozuka
    Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
    Biol Blood Marrow Transplant 22:843-9. 2016
    ..Polymorphic variants of certain genes involved in gemcitabine metabolism and DNA damage repair pathways may be potential biomarkers for clinical outcome in patients with refractory/relapsed lymphoid tumors receiving Gem/Bu/Mel. ..
  49. doi request reprint The emerging role of gemcitabine in conditioning regimens for hematopoietic stem cell transplantation
    Emily Wang
    Department of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, Texas Electronic address
    Biol Blood Marrow Transplant 20:1382-9. 2014
    ..The positive results suggest a potential future role for gemcitabine and necessitate the need to conduct studies to further define its role. ..
  50. ncbi request reprint Progressive multifocal leukoencephalopathy after allogeneic bone marrow transplantation for acute myeloid leukemia
    Hans C Lee
    From the Division of Cancer Medicine, Department of Infectious Disease, and Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas
    J Natl Compr Canc Netw 12:1660-4; quiz 1664. 2014
    ..Although immunosuppression is an unavoidable risk of allogeneic BMT, these cases highlight a rare, yet fatal, consequence of prolonged T-cell lymphopenia and impaired cellular immunity after allogeneic BMT in this patient population. ..
  51. ncbi request reprint Prognostic value of nodal ratios in node-positive breast cancer
    Wendy A Woodward
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:2910-6. 2006
    ..Here we examine the data supporting the use of nodal ratios in breast cancer prognosis and consider the potential advantages and disadvantages of including nodal ratios in breast cancer staging...
  52. ncbi request reprint Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule
    M Santisteban
    Departamento de Oncología Médica, Clinica Universitaria de Navarra, Pamplona, Spain
    Clin Transl Oncol 9:465-7. 2007
    ....
  53. ncbi request reprint High-dose chemotherapy for breast cancer: is another look warranted?
    Yago Nieto
    Blood and Marrow Transplant Program, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, B 190 Denver, CO 80262, USA
    Curr Opin Oncol 16:114-9. 2004
    ..The authors review the main research results of high-dose chemotherapy for breast cancer in 2002 to 2003...
  54. ncbi request reprint Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant
    Yago Nieto
    Bone Marrow Transplant Program and Departments of Pathology and Biostatistics, University of Colorado, Denver, Colorado 80262, USA
    Clin Cancer Res 10:5076-86. 2004
    ....
  55. ncbi request reprint Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program, Denver, Colorado 80262, USA
    Clin Cancer Res 10:2609-17. 2004
    ..dissected nodes), tumor size, hormone receptors, and HER2. In the present study we intended to test this model prospectively in a second patient cohort. In addition, we analyzed the long-term overall outcome of our HDC trials...
  56. ncbi request reprint Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support
    Yago Nieto
    Bone Marrow Transplant Program, University of Colorado, Denver 80262, USA
    Biol Blood Marrow Transplant 10:415-25. 2004
    ..2). In multivariate analyses, the presence of OTCs had an independent adverse effect on outcome in HRPBC, but not MBC. Our observations imply a direct role of OTCs in posttransplantation relapse in HRPBC...
  57. ncbi request reprint DNA-binding agents
    Yago Nieto
    University of Colorado Bone Marrow, Transplant Program, Denver 80262, USA
    Cancer Chemother Biol Response Modif 21:171-209. 2003
  58. ncbi request reprint Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapy
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program, Denver, CO, USA
    Am J Clin Oncol 28:248-54. 2005
    ..The debate about the age effect in this population remains unsettled...
  59. ncbi request reprint Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program, Denver, Colorado, USA
    Biol Blood Marrow Transplant 11:297-306. 2005
    ..The notable activity of this regimen in treatment-refractory patients warrants its further evaluation...
  60. ncbi request reprint Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer
    Yago Nieto
    Bone Marrow Transplant Program and Department of Biostatistics, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Clin Cancer Res 10:7136-43. 2004
    ....
  61. ncbi request reprint Stem-cell transplantation for the treatment of advanced solid tumors
    Yago Nieto
    University of Colorado Health Sciences Center, 4200 East Ninth Avenue, B 190, Denver, CO 80262, USA
    Springer Semin Immunopathol 26:31-56. 2004
    ..This article reviews the results of the main phase II and III studies of HDC with ASCT, as well as the preliminary experience using allogeneic transplantation for solid tumors...
  62. ncbi request reprint Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program and Department of Pathology, University of Colorado, Denver, CO 80262, USA
    J Clin Oncol 20:707-18. 2002
    ..To study prognostic factors after high-dose chemotherapy (HDC) for patients with stage IV oligometastatic breast cancer...
  63. ncbi request reprint DNA-binding agents
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program, Denver, CO 80262, USA
    Cancer Chemother Biol Response Modif 22:163-203. 2005
  64. ncbi request reprint DNA-binding agents
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program, 4200 East Ninth Avenue, B 190, Denver, CO 80262, USA
    Cancer Chemother Biol Response Modif 20:197-225. 2002
  65. ncbi request reprint The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer
    Yago Nieto
    University of Colorado School of Medicine, Denver, CO 80262, USA
    Haematologica 88:201-11. 2003
    ..In most cases, the results of these trials are premature and contradictory. Furthermore, they have often been interpreted, incorrectly in this author's judgment, as proof of lack of benefit of HDC...
  66. doi request reprint The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review
    Denise M Oliansky
    Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Biol Blood Marrow Transplant 14:137-80. 2008
    ..conventional conditioning in older (>60 years) and intermediate (40-60 years) aged adults? (4) What is the impact on survival outcomes of unrelated donor HSCT vesus chemotherapy in younger (<40 years) adults with high risk disease?..
  67. ncbi request reprint The evolution of the evidence-based review: evaluating the science enhances the art of medicine--statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation
    Roy Jones
    Biol Blood Marrow Transplant 11:819-22. 2005